ERC/mesothelin is expressed in human gastric cancer tissues and cell lines

Ito,Tomoaki; Kajino,Kazunori; Abe,Masaaki; Sato,Koichi; Maekawa,Hiroshi; Sakurada,Mutsumi; Orita,Hajime; Wada,Ryo; Kajiyama,Yoshiaki; Hino,Okio

doi:10.3892/or.2013.2803

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines

Authors:
- Tomoaki Ito
- Kazunori Kajino
- Masaaki Abe
- Koichi Sato
- Hiroshi Maekawa
- Mutsumi Sakurada
- Hajime Orita
- Ryo Wada
- Yoshiaki Kajiyama
- Okio Hino
View Affiliations

Affiliations: Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, Department of Pathology and Oncology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, Department of Pathology, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, Department of Esophageal and Gastroenterological Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan
Published online on: October 22, 2013 https://doi.org/10.3892/or.2013.2803
Pages: 27-33
Copyright: © Ito et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

ERC/mesothelin is expressed in mesothelioma and other malignancies. The ERC/mesothelin gene (MSLN) encodes a 71-kDa precursor protein, which is cleaved to yield 31-kDa N-terminal (N-ERC/mesothelin) and 40-kDa C-terminal (C-ERC/mesothelin) proteins. N-ERC/mesothelin is a soluble protein and has been reported to be a diagnostic serum marker of mesothelioma and ovarian cancer. Gastric cancer tissue also expresses C-ERC/mesothelin, but the significance of serum N-ERC levels for diagnosing gastric cancer has not yet been studied. We examined the latter issue in the present study as well as C-ERC/mesothelin expression in human gastric cancer tissues and cell lines. We immunohistochemically examined C-ERC/mesothelin expression in tissue samples from 50 cases of gastric cancer, and we also assessed the C-ERC/mesothelin expression in 6 gastric cancer cell lines (MKN-1, MKN-7, MKN-74, NUGC-3, NUGC-4 and TMK-1) using reverse transcription-polymerase chain reaction, flow cytometry, immunohistochemistry and immunoblotting. We also examined the N-ERC/mesothelin concentrations in the supernatants of cultured cells and in the sera of gastric cancer patients using an enzyme-linked immunosorbent assay (ELISA). N-ERC/mesothelin was detected in the supernatants of 3 gastric cancer cell lines (MKN-1, NUGC-4 and TMK-1) by ELISA, but its concentration in the sera of gastric cancer patients was almost same as that observed in the sera of the normal controls. In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer.

View Figures

View References

1	Hino O, Kobayashi E, Nishizawa M, et al: Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol. 121:602–605. 1995. View Article : Google Scholar : PubMed/NCBI
2	Yamashita Y, Yokoyama M, Kobayashi E, Takai S and Hino O: Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 275:134–140. 2000.PubMed/NCBI
3	Hino O: Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med. 4:807–811. 2004. View Article : Google Scholar : PubMed/NCBI
4	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
5	Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hassan R, Remaley AT, Sampson ML, et al: Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 12:447–453. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shiomi K, Miyamoto H, Segawa T, et al: Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 97:928–932. 2006. View Article : Google Scholar : PubMed/NCBI
8	Inami K, Kajino K, Abe M, et al: Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep. 20:1375–1380. 2008.PubMed/NCBI
9	Shiomi K, Hagiwara Y, Sonoue K, et al: Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res. 14:1431–1437. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yen MJ, Hsu CY, Mao TL, et al: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res. 12:827–831. 2006. View Article : Google Scholar : PubMed/NCBI
11	Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
12	Atmaca A, Pauligk C, Steinmetz K, Altmannsberger HM, Jäger E and Al-Batran SE: Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. Oncology. 80:130–134. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wang L, Niu Z, Zhang L, et al: Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res. 40:909–916. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kawamata F, Homma S, Kamachi H, et al: C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol. Mar 20–2013.(Epub ahead of print).
15	Alvarez H, Rojas PL, Yong KT, et al: Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine. 4:295–301. 2008. View Article : Google Scholar
16	Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 96:11531–11536. 1999. View Article : Google Scholar
17	Baba K, Ishigami S, Arigami T, et al: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol. 105:195–199. 2012. View Article : Google Scholar : PubMed/NCBI
18	Einama T, Homma S, Kamachi H, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hino O and Maeda M: Diagnostic tumor marker of asbestos-related mesothelioma. Environ Health Prev Med. 13:71–74. 2008. View Article : Google Scholar : PubMed/NCBI
20	Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
21	Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M and Hino O: Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int. 59:161–166. 2009. View Article : Google Scholar : PubMed/NCBI
22	Onda M, Nagata S, Ho M, et al: Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res. 12:4225–4231. 2006. View Article : Google Scholar : PubMed/NCBI
23	Saeki H, Hashizume A, Izumi H, et al: The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma. Oncol Lett. 4:637–641. 2012.PubMed/NCBI
24	Sharon E, Zhang J, Hollevoet K, et al: Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med. 50:721–725. 2012. View Article : Google Scholar : PubMed/NCBI
25	Creaney J, Francis RJ, Dick IM, et al: Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 17:1181–1189. 2011.